Abstract
Background: The association between atopic dermatitis (AD) and cardio-metabolic risk factors is not yet established. Furthermore, no validated questionnaire-based method of identifying adults with AD is currently available. Objectives: To assess the cardio-metabolic risk in adults with a history of AD using 3 different questionnaire-based diagnostic criteria. Methods: We utilized data from a general population study including questionnaire data and objective measurements of 9656 Danish adults. To identify adults with a history of AD, we used a question regarding physician-diagnosed AD and 2 versions of the UK Working Party Diagnostic Criteria. Associations between AD status and cardio-metabolic endpoints were estimated using survey weighted logistic and linear regression analysis. Results: We identified 462 (4.8%) adults with self-reported physician-diagnosed AD, whereas 903 (9.4%) and 226 (2.3%) had AD according to the UK Working Party Criteria when at least 2 and 3of 4 minor criteria were fulfilled. The populations were not comparable in terms of occurrence of cardio-metabolic risk factors. For example, the prevalence of obesity was lower in participants with physician-diagnosed AD but overall higher in UK 2/4 and UK 3/4. Conclusion: Due to the heterogeneity in the captured study populations in terms of the studied outcomes and absence of a gold standard, no conclusions regarding the cardio-metabolic risk in adults with AD in a general population could be made. This study serves as an example of the challenges that are often encountered in questionnaire-based epidemiologic studies and highlights the need of better definitions for this patient group.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Allergy: European Journal of Allergy and Clinical Immunology |
| Vol/bind | 73 |
| Udgave nummer | 4 |
| Sider (fra-til) | 923-931 |
| ISSN | 0105-4538 |
| DOI | |
| Status | Udgivet - 2018 |
Finansiering
Drs. Thyssen and Andersen are supported by an unrestricted grant from the Lundbeck Foundation. We thank Rikke Kart Jacobsen for statistical support. Dr. Thyssen has attended advisory boards for Roche and Sanofi-Genzyme and received speaker honorarium from LEO Pharma and Galderma. Dr. Skov has received consultancy and/or speaker honoraria from Abbvie, Pfizer, Janssen-Cilag, Merck Sharp & Dohme, and Leo Pharma and is a member of the advisory boards of Abbvie, Pfizer, Janssen-Cilag, Merck Sharp & Dohme, Eli Lilly, Celgene and Novartis. Dr. Egeberg has received research funding from Pfizer and Eli Lilly, and honoraria as consultant and/or speaker from Pfizer, Eli Lilly, Novartis, Galderma and Janssen Pharmaceuticals. Drs. Andersen, Hamann, Gislason, Skaaby and Linneberg have no conflict of interests to declare. This research was performed independently through the authors’ academic university and hospital affiliations.
Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS